Navigation Links
Scientists Identify New Possible 'biomarker' for Pancreatic Cancer

University of Cincinnati researchers have identified a specific cell receptor, which they say is a potential biological target for pancreatic cancer.

Led by Dr. Andrew Lowy and Dr. Susan Waltz, the study found that the RON receptor tyrosine kinase was "over-expressed" in pancreatic cancer cells, suggesting that the receptor may also contribute to the disease's development.

The researchers say that their findings, published in the journal Cancer Research, may help scientists better understand and treat the disease that kills more than 33,000 people each year.

Published in the journal Cancer Research, this is the first study to establish the link between the RON receptor and pancreatic cancer. The report also tells that receptor tyrosine kinases are proteins on the cell surface used to activate specific body functions like cell growth and migration.

"A normal pancreas has very low levels of RON, but our study showed that as tumours progress, so does the level of RON expression in the pancreas cells -- and those over expressed levels were maintained in 'metastases,' the areas that the tumours spread to," explains Waltz, Associate Professor and Director of the Oncology Research Program, Surgery Department, Cincinnati University.

During the study, the researchers noted that the RON receptor was active in 93 per cent of pancreatic intraepithelial neoplasia, an early form of pancreatic duct cancer. They also observed that the receptor was present in 79 per cent of primary pancreatic cancers, and 83 per cent of metastatic cancers.

Waltz believes that the RON receptor's signalling pathways may be a key factor contributing to pancreatic cancer progression, and that it may give drug developers a new target for RON directed therapies that are more effective in treating the deadly disease.

"When cells became invasive, we saw higher levels of RON expression that correlated with the aggressive nature of this disease and cancer metastasis. Clearly, this signaling pathway is associated with pancreatic cancer and merits further investigation," Waltz said.

During the study, the researchers used the protein HGFL to activate the RON receptor.

They observed that though stimulating the RON receptor had no effect on pancreatic cell growth, blocking it with targeted antibodies killed more cancer cells than did the standard treatment drug gemcitabine alone.

"Our findings suggest that combining antibodies that block the RON receptor and the standard chemotherapy drugs might stop progression of pancreatic cancer more effectively. RON could be a promising molecular target for future cancer drug development," says Waltz.

However, the researchers, who had reported in December last year the association between the RON receptor and breast cancer, say that further studies is needed before blockers for the RON receptors may be used for human testing.


'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... ... ... Gout is like no other joint pain. It strikes suddenly, like flicking on ... redness. It is triggered by the crystallization of uric acid within the joints. It ... to the February 2016 issue of Harvard Men's Health Watch. , The large joint ...
(Date:2/10/2016)... Carefree, AZ (PRWEB) , ... February 10, 2016 , ... ... coach in new book , Pioneering book "Better with Age: The Ultimate Guide to ... neuroplasticity can improve memory. The book’s publication date is March 16, 2016. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... FL 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – ... – 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... ... A new leadership team for Mid-South Youth Camp, operated by Freed-Hardeman University, will ... night, Feb. 8, prior to the evening session of the university’s 80th Annual Bible ... Camp, has been named director. Gayle McDonald, currently the assistant director of MSYC, will ...
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... HILLS, Calif. , Feb. 10, 2016  Rich ... "Company") today announced a 1-for-100 reverse split of its ... the opening of trading on Thursday, February 11, 2016. ... basis under new CUSIP number 76303T308 and temporary ticker ... will commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... MEMPHIS, Tenn. , Feb. 10, 2016 ... School of Nursing received an in-kind ... of a VeinViewer® Vision vein finder ... donation will help students as they learn ... blood, combining technology with traditional technique. ...
Breaking Medicine Technology: